Ortho Pharmaceutical Corporation

Adrian Thaler

Cynthia Anne Maryanoff

Frank John Villani, Jr

Ahmed F Abdel-Magid

Urs Eggmann

The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu)-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the &#x3b1;-carbon.

Liquid phase peptide synthesis of KL-4 pulmonary surfactant

The invention realtes to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu ) -Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the &agr;-carbon.

Liquid phase peptide syntheses of KL-4 pulmonary surfactant

The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu.sub.4).sub.4 -Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the .alpha.-carbon.

Growing community of inventors

Stetten, Switzerland

Adrian Thaler